Drug Approval | May 03, 2025
USFDA inspection at Concord Biotech’s API facility at Dholka
These observations are procedural in nature and none of them are related to data integrity
These observations are procedural in nature and none of them are related to data integrity
The Q1 2025 also witnessed a successful launch of Allegra D
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Alembic Pharmaceuticals commissions new facility at Pithampur
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Subscribe To Our Newsletter & Stay Updated
